Inhibiting C5AR1 enhances chemotherapy response by involving the suppression of CD8+ T-cell cytotoxicity, and a study suggests C5AR1-dependent signaling as an important immunomodulatory program for combinatorial cancer immunotherapy [50]. Here, CD8A is linked to cancer.